With regard to baseline clinical factors, CDKN2A/B deletion was not associated with differences in patient sex, age, or KPS compared with CDKN2A/B-intact glioblastomas (Supplemental Figure 2, B–D). Here, CDKN2A is linked to glioblastoma.